Table 3:

Comparison of patients positive for the swirl sign with and without hematoma growth

Patient CharacteristicsIncreased Hematoma Volume (n = 65)Stable/Reduced Hematoma Volume (n = 26)P Value
Age (median) (IQR) (yr)71 (63–76)66 (55–72).06
Male sex (No.) (%)25 (38.5)11 (42.3).81
Time to initial CT (median) (IQR) (hr)3 (1.7–6.6)4 (2.6–12.7).01
Time to second CT (median) (IQR) (hr)12 (4.2–23.8)26.8 (14.7–36.0)<.001
Initial hematoma volume (median) (IQR) (mL)24 (12.2–49.6)21.6 (10.3–38.5).37
PMHx (No.) (%)
    Hypertension46 (70.7)21 (80.8).43
    Hypercholesterolemia17 (26.2)6 (23.8)1.00
    Statin use22 (33.9)6 (23.8).45
    Diabetes16 (24.6)5 (19.2).78
    Ischemic heart disease15 (23.1)3 (11.5).26
    Atrial fibrillation23 (35.4)3 (11.5).018
Previous stroke
    Transient ischemic attack3 (4.6)1 (3.9)1.00
    Ischemic stroke (n = 207)8 (12.3)3 (11.5)1.00
    Hemorrhagic stroke3 (4.6)1 (3.9)1.00
Anticoagulant (No.) (%)
    Warfarin22 (33.9)1 (3.9).003
    Antiplatelet22 (33.9)6 (23.8).45
GCS on presentation (median) (IQR)14 (9.8–14)13 (11–14).13
INR (median) (IQR)1.2 (1.0–1.8)1.1 (1.0–1.1).01
Radiologic (No.) (%)
    Location supratentorial55 (84.6)23 (88.5).75
    IV extension17 (26.2)11 (42.3).35
    Midline shift33 (50.8)18 (69.2).16
  • Note:—GCS indicates Glasgow Coma Scale; PMHx, past medical history; IV, intraventricular; INR, international normalized ratio.